E

Elizabeth Garner

C-Suite Executive | Independent Board Member | Seasoned Pharma Leader | President-Elect American Medical Women's Association | Fighting Stigma, Advancing Therapeutics, and Increasing Equity in Women’s Health

Bryn Mawr, PA, US

Ask me about

Work experience

  1. May 2022 – present

    Ferring Pharmaceuticals

    Chief Scientific Officer, US
  2. November 2021 – present

    Chief

    Chief Member
    Chief is a private network built to drive more women into positions of power and keep them there. Chief is the only organization specifically designed for senior women leaders to strengthen their leadership journey, cross-pollinate ideas across industries, and effect change from the top down.
  3. July 2015 – present

    KNI Health Consultants, LLC

    Owner, President
    In addition to my fulltime role as CSO, I provide short term expert consulting through my LLC. I am qualified to provide consultation in a range of therapeutic areas, including cancer prevention and treatment, women's health, genetic testing, and surgical devices. I also provide insights on regulatory affairs including NDA submissions and FDA Advisory Committee preparation.
  4. July 2019 – May 2022

    ObsEva SA

    Chief Medical Officer
    As a member of ObsEva’s Executive Committee, I provide strategic leadership on the Company’s overall development strategy and frequently represents ObsEva to investor, Key Opinion Leader (KOL), and other key stakeholders. In my role as CMO, I lead our clinical science group, clinical operations, and pharmacovigilance.
  5. January 2014 – July 2019

    Agile Therapeutics

    Chief Medical Officer
    As an officer of Agile Therapeutics, I played a major role in strategy development for the company, including due diliegence evaluation of business development opportunities. As CMO I was responsible for all clinical research and development activities, including managing the clinical team, designing and leading all clinical trials and NDA submissions for Agile’s lead candidate product, the Twirla contraceptive patch, as well as development of Agile's follow-on pipeline. I also led the Medical Affairs, pharmacovigilance and medical information functions.
  6. January 2012 – January 2014

    Myriad Genetics

    Vice President Medical Affairs, Preventive Care
    Provide medical and scientific input in development of company strategy. Serve as medical and scientific resource, representing Myriad Preventive Care to key internal and external stakeholders. Oversee field-based Regional Medical Specialists in Preventive Care.
  7. Abbott
    January 2011 – January 2012

    Abbott

    Senior Medical Director
    I was a key member of the clinical development team for Elagolix (Orilissa-approved by FDA in 2018). I designed the pivotal Phase 3 endometriosis trials and provided extensive input into the design of the Phase 2 and 3 fibroid studies, including endpoint selection, patient reported outcomes, and statistical analysis.
  8. January 2010 – January 2011

    Merck

    Director
    Leader of Product Development Team for next generation HPV vaccine. Clinical lead for FDA and European filings, FDA Advisory Committee Meeting.
  9. January 2007 – January 2010

    Merck

    Associate Director
    Member of Gardasil clinical team. Protocol development, interpretation of study results, preparation of regulatory documents.
  10. January 2003 – January 2007

    Harvard Medical School

    Assistant Professor
  11. January 2003 – January 2007

    Brigham and Women's Hospital/Dana Farber Cancer Institute

    Gynecologic Oncologist
    Surgical and medical management of complicated gynecologic cancer patients. Research on ovarian cancer pathogenesis. Research on HPV vaccine awareness and acceptability.

Education

  1. Present

    Hillcrest School, Jos, Nigeria

  2. Present

    St. Saviors School, Ikoyi, Lagos, Nigeria

  3. 1989 – 1994

    Harvard Medical School

    M.D., Doctor of Medicine
  4. 1992 – 1993

    M.P.H., International Health
  5. 1985 – 1989

    AB, Biology, Music